Camelpox and Buffalopox: Two Emerging and Re-emerging Orthopox Viral Diseases of India

MANIMUTHU PRABHU1*, REVANAAIYAGOHISARADHYA2, SELVARAJ PAVULRAJ3, CHINNATHAMBI SURESH4, GOPAL SATISH5, RAJ KUMAR SINGH6

1Sheep Breeding Research Station, Tamil Nadu Veterinary and Animal Sciences University (TANUVAS), Sandynallah, The Nilgiris–643 237, Tamil Nadu, India; 2ICAR–National Institute of Veterinary Epidemiology and Disease Informatics (ICAR-NIVEDI), Bengaluru, Karnataka–560 024, India; 3Equine Pathology Laboratory, ICAR–National Research Centre on Equines (ICAR-NRCE), Hisar, Haryana–125001, India; 4Veterinary College and Research Institute (VCRI), TANUVAS, Ramayampatti, Tirunelveli–627 358, Tamil Nadu, India; 5Veterinary Dispensary, Panchetti–601 204, Tamil Nadu, India; 6ICAR-Indian Veterinary Research Institute (ICAR-IVRI), Izatnagar, Bareilly–243 122, Uttar Pradesh, India.

INTRODUCTION

Since last two decades, several unexpected outbreaks and epidemics of disease caused by viruses has been reported in humans and animals (Howard and Fletcher, 2012). This is the main constraint of majority of the developing countries where identification and control of emerging and re-emerging diseases are difficult and origin of diseases have major concern. Most of the emerging and re-emerging diseases causing agents are of zoonotic significance (Woolhouse and Gowtage-Sequeria, 2005). Almost a new virus has been emerging every year since the last two decades of which the pox viral diseases are one of the most significant diseases. Since eradication of smallpox infection, there are several reports on outbreaks of other poxvirus infections in humans (Singh et al., 2012). Initial outbreaks attributed to cowpox virus (CPXV) was recognized as caused by Vaccinia virus (VACV), species belongs to the genus Orthopoxvirus (OPV) (Van Regenmortel et al., 2000). Immunogenic similarity of Variola virus (VARV) with VACV helped in prevention smallpox infections in humans by mass immunization program executed.
by means of World Health Organization (WHO), resulted in eradication of smallpox from the earth in 1979 (Fang et al., 2006). Nevertheless, emergence of new VACV variants and bioterrorism represents key alarm and threat for more than half of the human populations of the world. Recent emergence of genetically related/allied OPVs has been reported all over the world viz. buffalopox, monkeypox and bovine vaccinia infections (Venkatesan et al., 2010a). Recently, OPV diseases outbreaks recorded more frequently in domestic animals as well as in humans (Shchelkunov, 2013), which reveals the presence of new condition in ecology and evolution of zoonotic OPVs. The pattern of evolution reminds that a VARV like viruses may emerge as zoonotic OPVs in due course of natural evolution process. Further, there is a persistent need for international control over the outbreaks in different countries of the world to provide a speedy reaction and prevention of outbreaks in developing/propagating epidemics. Camel populations in the world are estimated around 25.89 million, which spread around in 47 countries (FAOSTAT, 2012). Out of which, 85% camels resides in northern and eastern Africa and remaining populations are in Indian subcontinent and Middle East countries. India rank 7th in camel population of the world, and camel population is confined to north and western parts (Rajasthan, Haryana, Punjab and Gujarat states) of the country where 93.12% of Indian camel population inhabitates (Meena, 2014). In India, camel represents about 0.08% of the total livestock population (http://dahd.nic.in). The camelpox infection is reported in places where the presence of large populations of camels and the migration infected animals to new herds makes continues movement and persistence of virus in herds as possible (Fowler, 2010). The buffalo contributes around 21.23% of the total livestock population with the population of about 108.7 million buffaloes in the country as per 2012 Census (http://dahd.nic.in). There are no inhibitions for the possible re-occurrence of smallpox infections in humans in future due to natural evolution process of the currently circulating zoonotic OPVs. Continuously increasing zoonotic OPVs infections in the human populations in the absence of mass smallpox vaccination, increases the probability of emergence of new variants of viruses, which may be very dangerous for human life. Therefore this review focuses on two important OPVs existing in India – the camelpox and the buffalopox infections, particularly on their origin, epidemiology, clinical picture, diagnosis, preventive measures and global impact on veterinary and public health.

CAMELPOX

Camelpox is the most important acute contagious OPV disease of camelids (Camelus bactrianus and Camelus dromedarius) (Azwai et al., 1995). The disease was first reported in between 1893 and 1902 from Russia (Wernery and Kaaden, 2002), Rajaputana and Punjab parts of India (Leese, 1909) and later from different parts of the world (Figure 1) (Hafez et al., 1992). It is endemic in camel-rearing countries of Africa and Middle East Asia.
in which places camels are reared for milk and draught. It is economically significant disease of camels in terms of morbidity and mortality, weight loss and reduction in milk yield (Jezek et al., 1983). The disease commonly seen in younger camels, between 2 to 3 years of age and outbreak of disease is allied with poor nutrition and weaning. Clinically, camelpox infections may occur as any of three forms viz. severe, generalized milder, localized forms. Generalized and localized forms of infections mainly observed in young and older animals respectively. Morbidity, mortality and case fatality rates (CFR) may ranges from 30 to 90%, 1 to15% and 25% respectively (Al-Ziabi et al., 2007). The recovered animals may acquire life-long protective immunity to re-infection of homologues virus (Wernery and Kaaden, 2002).

Disease Classification
Camelpox is a notifiable skin disease of camelids as classified by Office International des Epizootics (World organization for animal health) (Elliot et al., 2008). Camelpox virus (CMLV) is primarily a disease of camels and so far infection in humans has not received much attention. Previously, the CMLV infection was thought to be a potential zoonotic agent to humans (Leese, 1909; Davies et al., 1975) as evidenced by smallpox-unimmunized individuals in Somalia (Kriz, 1982; Jezek et al., 1983). Recent reports indicate that CMLV can infect camel handlers under certain conditions (Bera et al., 2011).

Geographical Distribution
Even though, causative agent was not identified and isolated till 1969 (Sadykov, 1970), camelpox infection was a well-known disease in different parts of camel rearing countries (Figure 1) (Elliot et al., 2008). The infection is endemic in the Middle East countries (Iraq, Iran, Saudi Arabia, United Arab Emirates and Yemen), in Asia (India, Pakistan and Afghanistan) in Africa (Kenya, Egypt, Algeria, Somalia, Mauretania, Ethiopia, Oman, Sudan Nigeria and Morocco) and in the southern parts of former USSR (Chauhan and Kaushik, 1987; Hafez et al., 1992; Rennner-Muller et al., 1995; Khanna et al., 1996; Marodam et al., 2006; Bhanuprakash et al., 2010a, 2010b; Duraffour et al., 2011; Balamurugan et al., 2013). Lately, the outbreaks...
were also recorded from Syrian provinces namely, Hama and Duma (Al-Ziabi et al., 2007) and in India (Figure 2) (Bhanuprakash et al., 2010a; Bera et al., 2011).

**Etiological Agent**
Camelpox is caused by CMLV, a linear double stranded DNA virus with a genome size of 205.719 kbp, belong the genus Orthopoxvirus (OPV), subfamily Chordopoxvirinae of Poxviridae family (ICTV, 2005). Initially it was considered as smallpox-like disease causing agent at the time of smallpox virus eradication (Baxby, 1972), later it lead to identification, isolation and characterization of CMLV. The average virion size is 224 × 389 nm. CMLV remains one of the neglected members of the OPVs till now. It is impossible to differentiate from the prototypic member of the family Poxviridae, Vaccinia virus (VACV) (Gubser and Smith, 2002; Sheik et al., 2009). Nevertheless, structure of the genome and DNA sequences for all open reading frames (ORFs) phylogenetic analysis revealed that CMLV is distinct from VACV and VARV (Afonso et al., 2002). But the DNA sequences of CMLV were most related to VARV (Gubser and Smith, 2002).

**Physiochemical Properties of CMLV**
CMLV is like any other OPVs, shows unpredictable responses to different physical/chemical agents. CMLV is resistant to ether and sensitive to chloroform (Tantawi et al., 1974; Davies et al., 1975). It is more sensitive to extreme ranges of acidic and alkaline conditions (Davies et al., 1975). The virus can be easily killed by boiling or autoclaving at least 10 min and few minutes in ultraviolet rays (Coetzer, 2004). The detailed difference in the physico-chemical properties of different CMLV strains has been reviewed earlier (Duraffour et al., 2011). CMLV (H 520 strain of Kenya) haemagglutinates cockerel erythrocytes (Davies et al., 1975). But, the 78 strain showed agglutination with chicken RBCs at room temperature (pH 6-8) with low titer (Al-Falluji et al., 1979). In general, poxvirions show high environmental stability (tolerance to temperature, pH and chemicals) and may stay as contagious for several months (Rheinbaden et al., 2007).

**Host Range**
Naturally, CMLV has extremely narrow host range, which primarily affects camels along with mild infection in humans as per recent reports. Experimental inoculation of CMLV in sheep, goat, rabbit, guinea pig, rat, hamster and mice has not been successful so far in establishment of infection (Ramyar and Hassami, 1972; Bhanuprakash et al., 2010b). Apart from natural host, monkeys and suckling mice have been successfully infected experimentally (Baxby, 1972). In contact sheep and cattle with naturally infected camels do not acquire the infection. However, certain isolates of CMLV (CP/Nw/92/2) isolated from Sudan were able to induce local skin lesions in chickens (Khalafalla and Mohamed, 1998).

**Disease Transmission**
The disease is transmitted naturally by direct contact of infected animals with susceptible animal or by indirect contact with contaminated environment (Al-Ziabi et al., 2007). The route of transmission is via inhalation or through skin abrasions. The infected camels shed the virus in secretions like saliva, milk, ocular and nasal discharges (Ramyar and Hassami, 1972). The dried scab shed from the infected animals is rich in virus and is the potential source for environmental contamination for at least four months. Ticks population in rainy season is speculated to be involved in the spread of camelpox infection (Wernery et al., 1997b). Conversely, mosquitoes, biting flies and other vectors are also involved in transmission of the infection (Bhanuprakash et al., 2010a). Camelpox outbreaks were reported in isolated pockets in different parts of the world and isolated viruses of in different degree of virulence (Duraffour et al., 2011), which raises the question of wild animals as a reservoir of infection for CMLV other than camels. Further, outbreaks commonly seen during rainy seasons when rodents are active, so it is possible that, rodents may act as natural carriers of CMLV (Shchelkunov, 2013).

**Environmental and other Predisposing Factors**
Outbreaks occurs frequently in temporal regions due to continuous movement of camels for watering and grazing which leads to mixing of different herds and introduction of new animals into a herd (Azwai et al., 1996). Involvement of arthropod vector may also be the potential source which needs to be investigated. The other factors which influences the occurrence of the disease includes age, stress, nutritional status of the animals, season, migration of animals, presence of other diseases in incubation phase and of course the virulence of the virus (Davies et al., 1975; Jezek et al., 1983; Al Hendi et al., 1994).

**Prevalence of Disease in Animals and Humans**
The disease may cause both tangible and intangible losses due to morbidity and high mortality in young animals with weight loss, reduced milk production, draft power and trade constraint of infected camels and their by-products (Jezek et al., 1983). Morbidity may vary based on spread virus strain in particular herd. Serological surveys from several developing countries like Kenya, Sudan and Libya exposed the prevalence of high antibody level to camelpox virus infection (Wernery and Kaaden, 2002). The incidence rate and case fatality is more in males than females (Jezek et al., 1983) and the mortality is higher in young animals than adults (Kritz, 1982). The mortality may ranges from 10 to 28 % and 25 to 100 % in adult and young animals respectively (Bhanuprakash et al., 2010a). Current literature indicates the occurrence of mild zoonotic cases of infection in people who handle the infected animals (Bera et al., 2011).
CLINICAL MANIFESTATIONS IN ANIMALS
The incubation period ranges from 4–15 days followed by pyrexia. Later, there will be papules formation on the lips, afterwards papules became vesicles, pustules and scabs formation (Bhanuprakash et al., 2010a). The disease occurs commonly as in-apparent form with mild infection limited to the skin, rarely severe systemic infections may appear, varying based on the strains of CMLV (Wernery and Kaaden, 2002). The infection is characterized by pyrexia, lymphadenopathy and typical pox lesions on skin (Wernery et al., 1997a). These skin lesions primarily may appear on the head, eyelids, nostrils, ears and in the severe cases swelling of whole head may be seen. In acute cases intense skin pruritis also observed. Later, the skin lesions extend to the neck, mammary glands, genitalia, limbs, and perineal region. The generalized form of lesions may appear in entire body and takes about 4–6 weeks to heal. In these cases, pox lesions may be seen on the mucous membranes of the mouth, digestive and respiratory tracts. Normally, CMLV infection is of benign type in adult camels. Nevertheless, severe forms infection causes loss of vision with increased CFR in young camels. Further, abortions, still birth, loss of weight with reduced milk production may also be seen in adults (Hiiggins et al., 1992; Kritz, 1982; Khalfalla and Mohamed, 1996; Hussien and Al-Mufarrej, 1999; Bhanuprakash et al., 2010a). Infected animals may show ptyalism and lacrimation with mucopurulent nasal discharge. Sometimes, systemic form of infection causes anorexia, diarrheea and death due to secondary bacterial complications and septicemia caused by Staphylococcus aureus ((Nothelfer et al., 1995; Wernery and Kaaden, 2002).

ZOONOTIC SIGNIFICANCE
CMLV was found to be zoonotic in nature (Leese, 1909; Davies et al., 1975) with little evidence till recent days. At times, the virus could be pathogenic for man like cowpox and monkey pox (Marennikova et al., 1974). Study for the vulnerability of humans to camelpox virus infections was undertaken in Somalia in early 1980s. Kritz (1982) and Jezek et al. (1983) revealed that most of camel herders never had smallpox vaccination. Skin rashes were observed in few herders, although clinical samples collected from affected individuals never revealed OPV, further transmission of camelpox was not reported. It could be one of the potential bio-warfare agents (Marennikova et al., 1974; Balamurugan et al., 2008). Immunocompromised humans were more susceptible to CMLV infections (De Clercq, 2002). The possibility of zoonotic transmission was not decisively confirmed till 2010, while the etiological agent was isolated from skin lesions and pustules on the hands of camel herders in Indian who were in contact with infected animals (Bera et al., 2011). The skin lesions remain localized without transmission between humans (Bray and Babiuk, 2011). The clinical manifestations in infected humans may include fever (101–102°F), itching, erythema along with formation of localized edema, papules, vesicles, ulceration and scab formation over fingers and hands. The lesions may be painful initially; later, skin vesicles may burst and become dry leaving scars formation (Bera et al., 2011).

DIAGNOSTIC PROCEDURES
Numerous diagnostic methods have been developed for diagnosis of camelpox virus infection (Pfieffer et al., 1998). Tentative diagnosis for CMLV infection may be made based appearance clinical signs. Conversely, camels with mild clinical signs should be discriminated from other diseases like papilloma virus infections, contagious ecthyma (orf) and insect bites. Camelpox infections are usually diagnosed based on appearance of clinical signs, epizootiological, postmortem findings (Buchnev et al., 1987), virus isolation and identification, electron microscopy and antigen capture ELISA (Bhanuprakash et al., 2010a). Restriction enzyme analysis and transmission electron microscopy (typical brick-shaped) can be used for differentiation of parapoxviruses from other OPVs (Murphy et al., 1999; Al-Ziabi et al., 2007).

VIRUS ISOLATION
For isolation of camelpox virus, embryonated chicken eggs aged 11–13 days, primary cell culture and cell lines are used. When inoculated into the 11 to 13-day old embryonated chicken eggs through chorioallantoic membrane route (CAM) produces greyish white, dense, pock lesions on the surface of CAM after 5 days. In contrast, Vero cell line adapted viruses produces longer, opaque, white proliferative, tigroid pock lesion on CAM (Marodam et al., 2006). The cell lines like HeLa, MA–104, WISH, GMK-AH1, BSC–1, Vero, baby hamster kidney cells and MS monkey kidney cell lines can be used (Baxby, 1972). Primary cell cultures viz. lamb testis, lamb kidney, calf kidney, camel embryonic kidney, and chicken embryo fibroblast can also appropriate for isolation and propagation of CMLV (Davies et al., 1975; Tantawi et al., 1974; Bhanuprakash et al., 2010a). CPE of CMLV in Vero cells may appear like rounding of cells, vacuolization of cytoplasm, formation of multinucleated giant cell with syncytia and cytolysis (Pfieffer et al., 1996; Marodam et al., 2006).

SEROLOGICAL TESTS
Antibodies against poxvirus can be easily detected in animal’s serum than virus isolation (Marennikova, 1975). CMLV and parapox antibodies never cross react and infections of camel orf and camelpox can be distinguished using serological methods. Several serological tests are available to identify camelpox which had been given in detail (Bhanuprakash et al., 2010b). Conventional serological tests like haemagglutination (HA), haemagglutination inhibition (HI), serum neutralization test (SNT), ELISA, Western blot analysis, complement fixation test (CFT) and fluorescent antibody tests (FAT) were utilized...
for detection of CMLV antibodies (Al Hendi et al., 1994; Marrenikova et al., 1974; Schgal, 1977; Davies et al., 1975; Bhanuprakash et al., 2010b; Tantawi et al., 1978; Al-Falluji et al., 1979; Azwai et al., 1996). SNT is the routinely used confirmatory test for OPV diagnosis in majority of laboratories (Boulther et al., 1971).

**MOLECULAR DIAGNOSTIC TESTS**

In recent times, PCR based on species specific C18L gene have been utilized to distinguish CMLV from buffalopox virus (BPXV) and other OPVs (Balamurugan et al., 2009). OPV genus specific PCR based on A-type inclusion protein (ATIP) gene of CMLV yields 881 bp specific amplicon (Meyer et al. 1994), while, PCR based on hemagglutinin (HA) - gene yields 1100 bp amplicon (Damaso et al., 2000). Later, the species- specific (CMLV) single PCR assays were employed to confirm CMLV. CMLV specific tumor necrosis factor binding protein receptor-II (TNFR-II) gene gave 270 bp amplicon (Lapa et al., 2002; Marrodan et al., 2006). Further, PCR based on C18L gene and DNA pol gene also developed (Balamurugan et al., 2009)

Diagnosis of OPV genome by real-time quantitative PCR was developed by Nitsche et al. (2004) which were more quick and reliable method for OPV and VARV diagnosis. Both SYBR Green based (Balamurugan et al., 2009) and TaqMan probe based (Venkatesan et al., 2012a) real time PCR developed for brisk and sensitive method of CMLV detection. The fluorescence resonance energy transfer (FRET) based real-time PCR assay also useful in accurate diagnosis of CMLV infection (Panning et al., 2004). Of late, Venkatesan et al. (2012b) developed a simple and rapid field application diagnostic tool, called loop-mediated isothermal amplification assay (LAMP) which targeted C18L gene and evaluated with samples from field. This novel approach is specific and highly sensitive, which can be performed in rural diagnostics laboratories in developing countries like India.

**PREVENTION AND CONTROL STRATEGIES**

Prevention and control measures against sporadic cases of camelpox infection are very important in countries like India (Balamurugan et al., 2013). The restriction of animal movement, sanitary measures and isolation of the infected animals from healthier ones restrict the spread of the infection. Vaccination is the most economical and effective method to control camelpox. It is not necessary to vaccinate camels in all over the world. As an alternative, ring vaccination strategy can be employed during outbreak. It was more successful in last phase of the smallpox eradication campaign, in which rigorous and thorough monitoring and surveillance of disease was utilized for disease diagnosis followed by immunization of all animals in nearby associates and further sustained monitoring of disease to make sure no more diseases (Duraffour et al., 2011). Protective immunity in camelpox infection is both humoral and cell mediated (Elliot et al., 2008). Nevertheless, antibodies in circulation may not necessarily correlate with protective immune status of the animal (Wernery and Kaaden, 2002). Recovered animals become lifelong immune to re-infection. Live attenuated vaccines provide longer duration of protection for at least 6 years (Wernery and Zachariah, 1999), and inactivated viral vaccine offers protection for one year (Elliot et al., 2008).

**THERAPEUTIC MANAGEMENT**

Therapeutic management for post exposure camelpox infection has not been reported in detail yet. Treatment approaches in severe cases were aimed in control of secondary bacterial infections either by parental or topical applications of broad spectrum antibiotics or antimicrobials and vitamins (Wernery and Kaaden, 2002). The alternative treatment could be use of antiviral agents to manage camelpox infections, particularly in young camels. HDP-cidofovir or CMX001 is the recently developed potential oral anti-poxviral drugs. Nevertheless, in few cases, some resistant camelpox viruses are very hard to treat with cidofovir, but virulence of these viruses may be attenuated in due course of treatment (Smee et al., 2002). Another novel compound named ST-246 which is a potent and effective against majority of OPVs including CMLV. The activity of the molecular compounds like CMX001, Cidofovir, and ST-246 have been tested and evaluated only in vitro and are of potent inhibitors of CMLV replication (Duraffour et al., 2010; 2011). Further, ST-246 and CMX001 can be administered orally which is more attractive and promising in veterinary field (Duraffour et al., 2007).

**VACCINES**

In earlier days, an ancient method of scarification with mixture of camelpox infected crusts and milk (lactotherapy) was practiced in Punjab region of India (Leese, 1909), past USSR and Arabian Bedouin to contain camelpox infections (Bhanuprakash et al., 2010a). The self-limiting nature of camelpox virus infection in humans reveals that it might be used as live virus vaccine against smallpox and old records point out that immunization of camelpox crust material was in use for that purpose in Iran, as long before cowpox method of immunization developed by Jenner (Tadjbahsh, 1994; Bray and Babiuk, 2011). Later in 1973, there was information on presence of camelpox virus vaccines from Russia, made out of VACV, not from CMLV due to antigenic similarity between CMLV and VACV (Buchnev et al., 1987). As result, it was more likely to vaccinate camels with vaccinia strain virus to prevent camelpox infections. Two outbreak of camelpox infection in Iran (Baxby et al., 1975) and Bahrain (Higgins et al., 1992) were effectively contained by vaccinating camels with the vaccinia-strain EA8 and vaccinia Elstree strain/Lister strain, respectively (Bhanuprakash et al., 2010a). Of late, several reports of inactivated camelpox vaccines with variable suc-
cess have been reported from Saudi Arabia (Hafez et al., 1992), Morocco (El-Harrak et al., 1991, 1998), and UAE (Wernery et al., 1997a; Kaaden et al., 1992; Wernery and Zachariah, 1999; Wernery and Kaaden, 1995; Wernery et al., 2000). The formalinized aluminium hydroxide adjuvanted camelpox virus vaccine (CMLV strain T8-1984) which gives protection from infection for one year is available in Morocco (Elliot et al., 2008). This vaccine is prepared and distributed by Biopharma® which was reported to be safe in young and adult camels, further it induces neutralizing antibodies against CMLV (El Harrak and Loutfi, 2000) and necessitates annual booster immunization.

At the same time, attenuated strains of viruses were utilized in UAE and Saudi Arabia for manufacturing attenuated live vaccine (Nguyen et al., 1996). The UAE research group developed the stable fetal dromedary skin cell line (Dubca) for isolation and characterization of CMLV (Kloppries, 1993; Kaaden et al., 1992; Kaaden et al., 1995) which conferred protective immunity for maximum of 6 years following immunization in two animals. Even then, secondary booster immunization is suggested in young animals less than 6 months of age (Hafez et al., 1992). Of late, India has been able to produce a live Vero cell attenuated vaccine using an indigenous isolate (Bhanuprakash et al., Unpublished data). However, there is imperative to have a thermostability of these poxviral vaccines which has been studied in detail for the same camelpox vaccine (Prabhu et al., 2014), which may make possible their use in dry and hot regions of the country where outbreak of disease is common.

BUFFALOPOX

Buffalopox is a highly contagious acute viral disease of buffaloes, with 80% morbidity in affected herd population (Bhanuprakash et al., 2012). The first recorded incidence of buffalopox was reported in Lahore of undivided part of India in 1934 (Sharma, 1934) and was followed by frequent reports of outbreaks from various states of India (Sehgal et al., 1977). Disease also reported from Nepal, Bangladesh, Pakistan and Egypt (Singh et al., 2007a). In buffaloes the disease outbreaks are may be allied with elevated morbidity rate and loss of production (Chandra et al., 1987; Singh et al., 2006a, 2006b, 2006c, 2007a). The severity of the infection ranges from localized mild form to the infrequent severe generalized form. The infection poses economic impact due to reduced milk yield resultant from mastitis in milch animal and reduced working capacity in draft animals (Bhanuprakash et al., 2010c). Although buffaloes are commonly infected, cattle and human beings are infrequently get infection. Transmission potential of BPXV includes cattle, buffaloes and humans imply the potential re-emergence of the infection in Indian subcontinent as like VLV outbreaks observed in other countries in recent years (Singh et al., 2012).

DISEASE CLASSIFICATION

The Joint Expert Committee on Zoonosis confirmed buffalopox is one of the potential zoonotic diseases and transmission mode of buffalopox to human beings are alike that of cowpox infections (FAO/WHO, 1967; Chandra et al., 1987). In human, gross lesions may appear in animal attendants and milk-men who are in close proximity with affected buffaloes.

GEOGRAPHICAL DISTRIBUTION

Buffalopox is endemic with increasing trend in India (Prabhu et al., 2012) and outbreaks are reported from Maharashtra, Gujarat, Rajasthan, Andhra Pradesh, Tamilnadu and Karnataka states in India (Figure 3) (Venkatesan et al., 2010b; Bhanuprakash et al., 2010c; Chandranaiak et al., 2011; Gurav et al., 2011). Apart from Egypt, India, it is also been reported from several other countries namely Italy, Russia, Pakistan, Indonesia, Bangladesh and Nepal (Singh et al., 2012). In Pakistan, buffalopox caused a nosocomial infection in human beings (Zafar et al., 2007; Milton et al., 2015).

ETILOGICAL AGENT

The etiological agent of buffalopox infection in buffalo is buffalopox virus (BPXV). It is grouped in the subgroup of Chordopoxvirinae in the genus Orthopoxvirus (OPV) in the family Poxviridae (Van Regenmortel et al., 2000). The BP4 (Hisar) strain is considered as reference virus strain in India (Singh and Singh, 1967; Baxby and Hill, 1969). BPXV is close to the clade of VACV. In addition, studies on analyses of envelope (Singh et al., 2006b) and B5R (immunogenic proteins) genes (Singh et al., 2007b) of BPXV exposed a close association between BPXV and VACVs. Further, nucleotide and deduced amino acid sequences showed high identity of sequence with VACV (99%) and C18L gene showed that BPXV isolates clustered into a different group which is distinct from VACV (Singh et al., 2008 and 2012).

PHYSICOCHEMICAL PROPERTIES OF BPXV

BPXV is least sensitive to ether and sensitive to bile salts, chloroform, extreme ranges of pH and heat (Lal and Singh, 1977). Heat inactivation of BP4 strain virus to 56°C for 90 minutes resulted in complete loss of infectivity (Chandra et al., 1987), whereas BPXV isolated from 1980 outbreak in Hisar, Haryana, India (strain BPH-80) showed loss of infectivity at 56°C in 60 min (Kumar et al., 1987). Heat inactivation rate is higher in the presence of bivalent Mg++ cations. Though sensitive to heat, the BPH-80 strain of BPXV can produce pock lesions on CAM of embryo-nated chicken eggs incubated at 40.5±0.5°C, in contrast BP4 strain of BPXV failed to produce such lesions. But, all these strains showed pock lesions at 38±0.5°C incubation (Kumar et al., 1987; Singh et al., 2007a).

October 2015 | Volume 3 | Issue 10 | Page 533
Figure 3: Epidemiology and geographic distribution of buffalopox infection in Indian states

**Host Range**
Buffalopox is mainly a disease of domestic buffaloes (*Bubalus bubalis*) (Venkatesan et al., 2010b), and occasionally causes limited lesions in milch cows and occasional oro-pharyngeal lesions in human beings due to consumption of unpasteurized milk (Damaso et al., 2000; Dumbell et al., 1993). Buffaloes of all age groups and both sexes are affected, but the disease is severe in young and old animals (Bhanuprakash et al., 2010c). Experimentally, the buffalopox can be transmitted to buffaloes, cows (high dose of virus), guinea pigs, rabbits, suckling mice of Swiss white and Balb/C strain and chickens. But sheep, goat, fowl and adult mice of Swiss white and Balb/C strains are not suitable for experimental BPXV infections (Kumar et al., 1987).

**Disease Transmission**
The buffalopox transmission in animals is natural. In humans, attendants and milkmen who are in close proximity with affected buffaloes are usually getting affected (Singh et al., 2006a). Though the vector transmission is not been proved, biting flies like *Musca vicina, Musca crosirostris* and *Lyperosia exigua* have been reported to aggravate sores in animals. Therefore, it has been believed that flies may be implicated in transmission of BPXV mechanically (Muralidharan et al., 1989). The influence of environment and predisposing factors in the occurrence of buffalopox infection has not been extensively studied and established. An increased transmission of BPXV in variable species, cows, buffaloes and human beings, suggests the re-emergence of buffalopox zoonoses (Bhanuprakash et al., 2010c; Venkatesan et al., 2010b). The outbreaks observed in different remote location of India may represent abundant of natural BPXV reservoir wild animals especially rodents. Hence, large scale study on the prevalence OPV in wild animals in India is of prime important (Shchelkunov, 2013).

**Prevalence of Disease in Animals and Human Beings**
The occurrences of buffalopox in buffaloes are allied with variable rate of morbidity, mortality and case fatalities. Mortality and case fatality rates are usually low. Human infection followed by outbreak in buffaloes has been reported since its first recorded incidence. Haemagglutinin (HA) and ‘A type’ inclusion (ATI) gene sequences pox virus isolates for cattle revealed that BPXVs circulates in cows too (Yadav et al., 2010) along with buffaloes and humans.
**Table 1: Recent zoonotic outbreaks of buffalopox and camelpox infections at different places of India**

| Area-Village/ State         | Year   | Number of Human cases | Identification/ confirmation test          | References                                      |
|-----------------------------|--------|-----------------------|-------------------------------------------|------------------------------------------------|
| Camelpox zoonosis           |        |                       |                                           |                                                 |
| Rajasthan, India            | 2009   | 3                     |                                           | Bera et al. (2011)                              |
| Buffalopox zoonosis         |        |                       |                                           |                                                 |
| Aurangabad, Maharashtra     | 2003   | -                     | CIE, SNT, PCR and Virus isolation         | Singh et al. (2006a)                            |
| TamilNadu                   | 2005-06| -                     | -                                         | Unpublished data; Singh et al. (2012)           |
| Kolhapur- Pune, Maharashtra | 2009   | 125                   | CIE, SNT, PCR, TaqMan PCR                 | Venkatesan et al. (2010b)                      |
| Thotapalligudur- Nellore, Andhra Pradesh | 2006-08 | 7 | CIE, SNT | Bhanuprakash et al. (2010c) |
| Aurangabad (Kathiawad region) | 2006-08 | 5 | CIE, PCR, Real time PCR, Virus isolation | Bhanuprakash et al. (2010c) |
| Aundh – Pune, Maharashtra   | 2006-08| 4                     | SNT                                       | Bhanuprakash et al. (2010c)                     |
| Ratadia – Sardar Krishinagar, Gujarat | 2006-08 | 9 | CIE | Bhanuprakash et al. (2010c) |
| Bavar – Sardar Krishinagar, Gujarat | 2006-08 | 11 | CIE | Bhanuprakash et al. (2010c) |
| Hisar                       | 2014   | 1 –Laboratory acquired | PCR                                       | Riyesh et al. (2014)                           |

(Singh et al., 2006a, 2007a; Kolhapure et al., 1997).

**CLINICAL MANIFESTATION IN ANIMALS**

The incubation period in animals is 2–4 days (Ghosh et al., 1977). The disease occurs both in mild and severe forms. In localized less severe form lesions are confined to the inguinal region, udder and teats (Sharma, 1934; Singh and Singh, 1967), above parotid gland, inner aspect and base of eyes and ear (Bhatia, 1936; Wariyar, 1937; Mallick and Dwivedi, 1982; Mallick, 1988); Secondary bacterial otitis may appear. Whereas in severe form (Chandra et al., 1987; Ramakrishna and Ananthapadmanabham, 1957) lesions are normally generalized and seen on the teats, udder, thighs and hindquarters of infected animals. In severe infections in milking animals may causes mastitis, with everlasting milk yield reduction in (Singh et al., 2006a). Further it leads to reduced working capacity of draft animals (Singh et al., 2007a; Venkatesan et al., 2010b).

**ZOONOTIC SIGNIFICANCE**

Buffalopox is an important zoonotic disease. Recurrent epidemics and transmission of BPXV in cattle, buffalo and human beings make a very vital public health apprehension after the termination of vaccination against smallpox worldwide (Raut et al., 1997; Kolhapure et al., 1997; Singh et al., 2006a, 2007a). Outbreaks of diseases were reported at some point of smallpox immunization in Egypt, and Indonesia and later from India (Kolhapure et al., 1997; Nedunchelliyan et al., 1992; Singh et al., 2006a), Pakistan (Qureshi, Personal communication) and Nepal (Venkatesan et al., 2010b). The report on recent zoonotic outbreaks is given in Table 1. Human including individuals immunized with smallpox vaccines also contract infection due to intimate association with infected animals, further, severity and extent of disease is much higher in non-vaccinated persons (Singh et al., 2007a). Disease mainly spread by milking of infected animals. Since early, manifestation of diseases in humans was observed in persons associated with pox-infected buffaloes, animal attendants and milkers. (Wariyar, 1937; Mehrotra et al., 1981; Ghosh et al., 1977; Kumar et al., 1987; Raut et al., 1997; Kolhapure et al., 1997; Singh et al., 2006a). The incubation period in humans ranges from 3–19 days after exposure (Ghosh et al., 1977). Both the genders and all age groups of human beings contract the disease. The clinical signs in human include fever (39.0°C – 40.5°C) for 2-3 days, subsequently skin eruptions may appear. The lesions appear as small, round nodule with umbilication with an erythematous base. The lesions sometimes contain pustular material with cheesy consistency. The size may increase from1–2 mm to 1 cm in diameter, and severity persists for 7–8 days (Zafar et al., 2007). BPXV lesions are similar to cowpox vesicular lesions, but less painful, in some cases may appear like VACV lesions. The gross lesions observed in face, forehead, hands, buttocks and legs with lymphadenopathy of dependent parts Transmissions between humans are not been documented (Bhanuprakash et al., 2010c; Gurav et al., 2011). However, after detailed analysis Kolhapure and his colleagues (1997) reported that the presence of serum antibodies in more than 70% of in-contact individuals and 17% of persons with no history of association with infected humans or buffaloes is a public health alarm and finding of antibodies in these persons may be the signal of subclinical infection which may act as reservoir common human
population to zoonotic BPXV. Furthermore, these viruses may obtain virulence after repeated passage in human beings which is obvious when comparing isolation of BPXV strains in recent poxvirus outbreak and the reference strain (BP4) isolated about 40 years ago (Kolhapure et al., 1997; Singh et al., 2007a).

**Diagnostic Procedures**

Clinical diagnosis can be made on the basis of clinical picture of typical pox lesions on udder, teats or affected body parts. But, it must be differentiated from other diseases affecting udder like cowpox, pseudo-cowpox and bovine herpesvirus mammillitis. Laboratory investigations are, therefore, essential for establishing a confirmatory diagnosis.

**Virus Isolation**

As like CMLV, for isolation of BPXV, embryonated chicken eggs, primary cell culture and cell lines are used. 10% scab suspension prepared in phosphate buffer or normal saline is used to inoculate either chorio-allaantoic membrane of chickens or specific hosts like buffalo or cattle. The virus produces large (0.8-1.5mm diameter) raised or flat and white or grey pocks without hemorrhage or central necrosis on chorioallantoic membrane (CAM) of chick embryo after 48-72 hrs infection and later the death of embryo (60-70% mortality). BPXV has been propagated in rabbit kidney (RK-13) cells, chicken embryo fibroblast cells, HeLa cells, pup kidney cell culture, Vero, BHK21 and also in BHK21 suspension cell cultures. BHK21 cells are more sensitive for primary isolation of BPXV from clinical samples.

The virus produces plaques of about 0.8 mm size diameter on RK-13 cells, 1-2 mm diameter on chicken embryo fibroblasts and 0.8-1.2 mm diameter on Vero cells. The cytopathic effect includes clumping and granularity in cytoplasm, rounding, cluster formation and syncitia. BPXV exhibits characteristic ‘rosette’ or ‘sun flower’ like haemadsorption with 0.4% fowl erythrocytes (Sehgal et al., 1977).

**Serological Tests**

Serological assays for detection of buffalopox infections include agar gel immunodiffusion test (AGID), serum neutralization test (SNT), counter-immunoelectrophoresis (CIE), immunoperoxidase test (IPT) and ELISA (Bhanuprakash et al., 2010c). In gel diffusion tests cross-reactivity of BPXV was observed with sheeppox virus (SPPV), goatpox virus (GTPV) and fowlpox virus (FPV) (Mathew, 1975). Further, BPXV antiserum may also cross-reacts with FPV in the HI test, but rabbit anti-VACV serum may not react with FPV in same test (Mathew, 1975).

Cross-precipitation and cross-neutralization tests revealed the subsistence of a close association of BPXV with VACV (Lal and Singh, 1973; Kataria and Singh, 1970; Singh and Singh, 1967; Baxby and Hill, 1971). Nevertheless, no cross reacting precipitation of BPXV was observed in swinepox virus (SWPV) in agar gel precipitation test (Lal and Singh, 1973; Baxby and Hill, 1971; Kataria and Singh, 1970; Singh et al., 2007a).

**Molecular Diagnostic Tests**

Several limitations are there in identification and differentiation of OPV’s by conventional serological and biological methods. Analysis of viral polypeptides with sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) facilitated differentiation of genus and species but closely associated members of same genus cannot be differentiated. However, restriction enzyme-DNA (RE-DNA) profiling can be utilized for identification of poxvirus but it necessitates propagation of virus and isolation of viral genomic DNA, which requires more time (Singh et al., 2007a). PCR based on HA genes have been used for diagnosis and differentiation of OPVs. Primers viz. CoPV-3 and CoPV-4 has been applied for diagnosis and differentiation of OPVs including CMLV, CPXV, MPXV, raccoonpox virus (RCNV), VACV and BPXV. These primers amplify 2.8, 3.7 and 3.2 kbp fragments in CMLV, CPXV and BPXV, respectively (Ropp et al., 1995). Inclusion gene is contained in two fragments of HindIII digest of BPXV genomic DNA. Primer pair of ATI-up and ATI-low amplify the fragment of the inclusion gene which is also utilized for discrimination of OPV. The amplified product size in BPXV is 1587 bp whereas1603, 1673 and 880bp in VACV-WR strain, CPXV-Brighton strain and CMLV CP-1 strain, respectively (Singh et al., 2007a). Further, DNA of CMLV and BPXV can be characterized and differentiated by using DNA amplification fingerprinting (DAF) by RAPD-PCR. At last, TaqMan probe-based quantitative real-time PCR (qRT-PCR) based on Ankyrin repeat protein (C18L) gene and duplex PCR based on DNA polymerase (DNA Pol) and C18L are used for discrimination of BPXV from other OPVs (Singh et al., 2008).

**Prevention and Control Strategies**

The control measures followed to manage camelpox can be applied for buffalopox too. Disease control measure is very difficult to imply in certain countries, in which the disease is endemic in nature and the restriction of animal movement is very difficult. In addition, the export of contaminated buffalo meat is major concern. Cultural issues, social beliefs and economic contemplation put off India from having a policy of buffalo/cattle slaughter (Singh et al., 2007a). In the absence of appropriate immunoprophylactic measures, movement control of animals, implementation of hygienic measures like isolation of the diseased animals is the effective method to control the spread of infection.

**Therapeutic Management**

Certain drugs effective against OPV either in vitro and/or in vivo are available viz. cidofovir, ST-246, STI-271,
Vaccines

Despite of zoonotic nature buffalopox, literature regarding immunoprophylaxis is scarce. Very few vaccines have been developed against BPXV infection, but none of the vaccine is available for commercial use. BPXV vaccines produced by β-propiolactone and formalin inactivated, saponin and aluminium hydroxide gel-adjuvanted vaccine were ineffective when challenged in rabbits (Mohanty et al., 1989a). Later, BPXV-BP4 strain adapted in chicken embryo fibroblast and Vero cells were reported to be effective in buffaloes and rabbits (Mohanty et al., 1989b) and rabbits, respectively (Dogra and Sharma, 1981). Further vaccine produced using field strain of buffalopox (BPXV-Vij96) virus caused buffalopox outbreak in Andhra Pradesh (India), attenuated in Vero cells has been developed at Indian Veterinary Research Institute, Mukteswar, Uttarakhand (Singh et al., unpublished data). Preliminary safety, efficacy and immunogenicity studies of both BPXV-BP4 and Vij96 attenuated virus vaccine candidates were studied in buffalo calves by experimental challenge revealed both the vaccines were safe and potent. Both vaccines were potent and efficient and as confirmed by seroconversion with raise in antibody titer and protection following challenge in buffalo calves. The warrant protective immune response, prepared vaccine was given intradermally at ventral aspect of the tail at the dose rate of 10^5 tissue culture infective dose (TCID50) (Bhanuprakash et al., 2012).

CONCLUSION

Cessation of immunization against smallpox infection due to its eradication since 1980's resulted in vulnerable naïve human population against diverse OPVs throughout the world. This altered nature of virus infections in humans were may be due to VACV vaccine strain adaptation in animals by continuous passage or intimate contact of vaccinated human beings with pet animals. Although it was believed as host specific and infects only camels, the recent report of camelpox advocates a possible public health impact of the disease and necessitates further investigation. If the situation continues with greater number of outbreaks than early, it may be the next target for us after the eradication of smallpox infection and poliomyelitis in humans and rinderpest in animals. Considering the increased incidence of disease, molecular epidemiology of virus, disease diagnosis and control measures are very important in reducing the transmission of CMLV in camels and humans in terms of public health significance. Control of emerging buffalopox infection in animals will be vital which may be disease of zoonotic significance. The condition is much deteriorated in present situations due to increased outbreak of buffalopox infections. It seems that the BPXV isolated from human beings in India increasingly adapted to human beings because of intimate association of humans with infected animals. Since chemotherapy against buffalopox is ineffective, further, use of antibiotics/antimicrobials to treat secondary bacterial infections in infected animals may predispose human health vulnerability due to chances of residual antibiotics residues in meat and milk. Meat form BPXV infected buffalo has several related implications at international level. This signify the requirement of comprehensive systematic investigations on molecular epidemiology, subsistence of reservoir host, transmission and molecular association of BPXV and CMLV in association with related viruses, which may help in implementation of preventive and control measures. Eradication of diseases at global level conventionally been related with actions on a global or international scale, as like present movement to eradicate poliomyelitis in humans. However, such kind of huge efforts may not be necessary for diseases like buffalopox and camelpox, due to the fact that outbreaks are confined to certain regions could be controlled.

ACKNOWLEDGMENT

The authors are thankful to the Pox Laboratory, Division of Virology, Mukteswar (Regional Station), ICAR-IVRI for the support. The authors also thankful to Dr. V. Bhanuprakash and Dr. V. Gnanavel for their kind support during camelpox and buffalopox research.

CONFLICT OF INTEREST

There is no conflict of interest.

AUTHORS CONTRIBUTION

Manimuthu Prabhu, Revanaiah Yogisharadhya and Raj Kumar Singh provided the main concept and designed the study. Chinnathambi Suresh and Gopal Sathish managed acquisition of data while Manimuthu Prabhu and Selvaraj Pavulraj analysed and drafted the manuscript.

REFERENCES

• Abu Alzein EM, Gameel AA, Ramadan RO, Housawi FM
  (1999). An eruptive moderate form of camelpox infection in dromedary camels (Camelus dromedarius) in Saudi Arabia. Rev. Sci. Tech. 18: 749-752.
• Afonso CL, Tulman ER, Lu Z, Zsak L, Sandybaev NT,
Al-Falluji MM, Tantawi HH, Shony MO (1979). Isolation, identification, and characterization of camelpox virus in Iraq. J. Hyg. Camb. 83: 267-272. http://dx.doi.org/10.1017/S0021970600002605X

Al-Ziadi O, Nishikawa H, Meyer H (2007). The first outbreak of camelpox in Syria. J. Vet. Med. Sci. 69(5): 541-543. http://dx.doi.org/10.1292/jvms.69.541

Azwai SM, Carter SD, Woldehiwet Z (1995). Monoclonal antibodies against camel (Camelus dromedarius) IgG, IgM and light chains. Vet. Immunol. Immunopathol. 45: 175-184. http://dx.doi.org/10.1016/0165-2427(94)00531-O

Azwai SM, Carter SD, Woldehiwet Z, Wernery U (1996). Characterization of camelpox virus from camels in Ethiopia. Arch. Virol. 128(1): 257-267. http://dx.doi.org/10.1007/s0070500000002-3

Balamurugan V, Bhanuprakash V, Hosamani M, Jayappa KD, Singh RK (2010a). Comparative sequence analyses of B5R gene of Indian camelpox virus isolates with other orthopoxviruses. Indian J. Virol. 21(1): 1-12. http://dx.doi.org/10.1007/s13337-010-0145-0

Baxby D, Hill BJ (1969). Buffalopox virus. A correspondence. Vet. Record. 85: 315. http://dx.doi.org/10.1136/vr.85.11.315

Baxby D, Hill BJ (1971). Characteristics of a new poxvirus isolated from Indian buffaloes. Archiv für die gesamte Virusforschung. 35: 70-79. http://dx.doi.org/10.1007/BF01249754

Baxby D, Ramyar H, Hessami M, Ghaboosi B (1975). A new orthopoxvirus from camels in Iran. Br. Vet. J. 131: 647-651. http://dx.doi.org/10.1136/bvj.131.7.647

Baxby D, Ramyar H, Tessami M, Ghaboosi B (1975). A comparison of the response of camels to intradermal inoculation with camelpox and smallpox viruses. Infect. Immun. 11: 617-621.

Baxby D (1972). Smallpox viruses from camels in Iran. Lancet. 7786: 1063-1065. http://dx.doi.org/10.1016/S0140-6736(72)92343-4

Bera BC, Shahnugasundaram K, Barua S, Venkatesan G, Virmani N, Ritesh T, Gulati BR, Bhanuprakash V, Vaid RK, Kakker NK, Malik P, Bansal M, Gadvi S, Singh RV, Yadav V, Sardarilal, Nagarajan G, Balamurugan V, Hosamani M, Pathak KML, Singh RK (2011). Zoonotic cases of camelpox infection in India. Vet. Microbiol. 152(1-2): 29-38. http://dx.doi.org/10.1016/j.vetmic.2011.04.010

Bhanuprakash V, Prabhu M, Venkatesan G, Balamurugan V, Hosamani M, Pathak KML, Singh RK (2010a). Camelpox: epidemiology, diagnosis and control measures. Exp. Rev. Anti-Infect. Ther. 8(10): 1187-1201.

Bhanuprakash V, Balamurugan V, Hosamani M, Venkatesan G, Chauhan B, Srinivasan VA, Chauhan RS, Pathak KML, Singh RK (2010b). Isolation and characterization of Indian camelpox virus. Trop. Anim. Health. Prod. 42: 1271-1275. http://dx.doi.org/10.1007/s11250-010-9560-z

Bhanuprakash V, Venkatesan G, Balamurugan V, Hosamani M, Yogisharadhyra R, Gandhale P, Reddy KV, Damle AS, Kher HN, Chandel BS, Chauhan HC, Singh RK (2010c). Zoonotic infections of buffalopox in India. Zoon. Public Health. 57(7-8): e149-e155.

Bhanuprakash V, Hosamani M, Balamurugan V, Singh RK, Swarup D (2007). In vitro antiviral activity of Eugenia jambolana plant extract on buffalopox virus: conventional and qPCR methods. Int. J. Trop. Med. 2: 3-9.

Boumedoune MA, Zare MK, Pezeshki H, Toviaz MG (2002). Isolation of camelpox virus from a camel in Morocco. J. Hyg. Epidemiol. Microbiol. Immunol. 6736(72):92343-4

Chaurasia BM, Singh RK, Hosamani M, Krishnappa G, Harish BR, Chethana CS, Renukaprasad C (2011). Comparative sequence analysis of BSR gene of zoonotic buffalopox virus with other orthopoxviruses. Trop. Anim. Health Prod. 43(2): 287-290. http://dx.doi.org/10.1007/s11250-010-9700-5

Chauhan RS, Khushik RK (1987). Isolation of camelpox virus in India. Br. Vet. J. 14: 581-582. http://dx.doi.org/10.1016/0007-1935(87)90050-9

Chandra R, Garg SK, Rana UVS, Rao VDP (1987). Pox infection in buffaloes. Farm Anim. 2: 57-59.

Chandranaiak BM, Singh RK, Hosamani M, Krishnappa G, Harish BR, Chethana CS, Renukaprasad C (2011). Comparative sequence analysis of BSR gene of zoonotic buffalopox virus isolates with other orthopoxviruses. Trop. Anim. Health Prod. 43(2): 287-290. http://dx.doi.org/10.1007/s11250-010-9700-5

Chandra R, Garg SK, Rana UVS, Rao VDP (1987). Pox infection in buffaloes. Farm Anim. 2: 57-59.

Coetzee JAW (2004). Poxviridae. In: Infectious Diseases of Livestock, Second Edition, Coetzee JAW, and Tustin RC. eds. Oxford University Press, Southern Africa, Vol. 2: 1265-1267.

Damaso CR, Esposito JJ, Condit RC, Moussatche N (2000). An emergent poxvirus from humans and cattle in Rio de Janeiro state: Cantagalo virus may derive from Brazilian smallpox vaccines: a comprehensive review. Exp. Rev. Vaccines. 11(13): 1333-1347. http://dx.doi.org/10.1586/erv.12.116

De Clercq E (2002). Cidofovir in the treatment of poxvirus infections. Antiviral Res. 92: 164-166. http://dx.doi.org/10.1016/j.antiviral.2011.09.006

Dorfler S, Andri K, Snoeck R (2010). Tecovirimat, a p37...
envelope protein inhibitor for the treatment of smallpox infection. IDrugs. 13: 181–191.

• Duraffour S, Meyer H, Andrei G, Snoeck R (2011). Camelpox virus. Antiviral Res. 92(2): 167–186. http://dx.doi.org/10.1016/antiviral.2011.09.003

• Duraffour S, Snoeck R, de Bos R, van Den Oord JJ, Crance JM, Garin D, Hruby DE, Jordan R, De Clercq E, Andrei G (2007). Activity of the anti orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antiviral Ther. 12: 1205–16.

• El Harrak M, Loutfi C (2000). La variolo del dromadaire chez le jeune au Maroc. Isolement et identification du virus. Mise au point du vaccin et application a la prophylaxie. Revue Elev. Med. Vet. Pays Trop. 53: 165–167 (French).

• EL-Harrak M, Loutfi C, Bernt F (1991). Isolement et identification du virus de la variolo del dromadaire au Maroc. Ann. Rech. Vet. 22: 95–98.

• EL-Harrak M (1998). Isolation of camelpox virus, development of an inactivated vaccine and prophylactic application in Morocco. Ins. Meeting on camel production and future perspectives, May 2-3, Al Ain, UAE: 736.

• Elliot H, Tupperainen E (2008). Camelpox. Manual of diagnostic tests and vaccines for terrestrial animals, Vol. 2, Chap. 2.9.2, p. 177–184.

• Fang Q, Yang L, Zhu W, Liu L, Wang H, Yu W, Xiao G, Tien P, Zhang L, Chen Z (2006). Host range, growth property, and virulence of the smallpox vaccine vaccinia virus Tian Tan strain. Virology. 335: 242–251. http://dx.doi.org/10.1016/j.virol.2005.02.014

• FAO/WHO (1967). Expert committee on zoonosis: Poxvirus infection. Third Report, WHO Technical Report Series, Geneva, p. 378.

• FAOSTAT (2012). Food and Agricultural Organization United Nations: 223-225.

• Fowler ME (2010). Medicine and Surgery of Cameldids. Wiley-Blackwell, London. http://dx.doi.org/10.1007/9781118785706

• Ghosh TK, Arora RR, Sehgal CL, Ray SN, Wattal BL (1977). An investigation of buffalopox outbreak in animals and human beings in Dhulia District (Maharastra State). Epidemiological studies, J. Com. Dis. 9: 146–147.

• Guibert C, Smith GL (2002). The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox. J. Gen. Virol. 83(4): 855 – 872.

• Gurav VK, Raut CG, Yadav PD, Tandale BV, Sivaram A, Pore MD, Basu A, Mouya DT, Mishra AC (2011). Buffalopox outbreak in humans and animals in Western Maharashtra, India. Prev. Vet. Med. 100(3-4): 242–247. http://dx.doi.org/10.1016/j.prevetmed.2011.03.008

• Hafez SM, Al-Sukayran A, dela Cruz D, Mazloum KS, Al-Bokmy AM, Al- Mukayyel A, Amjad AM (1992). Development of a live cell culture camelpox vaccine. Vaccine. 9(10): 533-539. http://dx.doi.org/10.1016/0264-410X(92)90353-L

• Higgins AJ, Silvey RE, Abedghafr AE, Kitching RP (1992). The epidemiology and control of an outbreak of camelpox in Bahrain. Proc. 1st. Int. Camel Conf. 101-104.

• Howard CR, Fletcher NF (2012). Emerging virus diseases: can we ever expect the unexpected? Emerg. Microb. Infect. 1: e46: 1-11. http://dx.doi.org/10.1038/embi.2012.47

• Hussein MF, Al-Mufarrij SL (1999). Some clinicopathological aspects of camelpox in Saudi Arabia. J. King Saud Univ. Sci. 11 (2): 113-120.

• ICTV (2005). Virus Taxonomy: 8th Report of the International Committee on Taxonomy of Viruses. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA. (eds), Academic Press

• Jezez Z, Kriz B, Rothbauer V (1983). Camelpox and its risk to the human population. J. Hyg. Epi. Microbiol. Immunol. 27: 29–42.

• Kaaden OR, Walz A, Czerny CP, Wernery U (1992). Progress in the development of a camelpox vaccine. Proc. 1st. Int. Camel Conf. pp. 47–49.

• Kaaden OR, Wernery U, Kloppers M (1995). Camel fibroblast cell line Dubca and its use for diagnosis and prophylaxis of camel diseases. Proc. Intl. Conf. Livest. Prod. Hot Climates. A49.

• Kataria RS, Singh IP (1970). Serological relationship of buffalopox virus to vaccinia and cowpox viruses. Acta Virol. 14: 301–311.

• Khalafalla AI, Buttner M, Rahi HJ (2003). Polymerase chain reaction (PCR) for rapid diagnosis and differentiation of Para- and orthopox virus infections in camels. FAO/ IAEA International Animal Production and Health in Developing Countries, 6-10 October-2003. Vienna, Austria.

• Khalafalla AI, El Dirdiri GA (2003). Laboratory and field investigations of a live attenuated and an inactivated camelpox vaccine. J. Camel Prac. Res. 10(2): 191-200.

• Khalafalla AI, Mohamed MEH, Ali BH (1998). Camel pox in Sudan. 1- Isolation and identification of the causative virus. J. Camel Prac. Res. 5(2): 229-233.

• Khalafalla AI, Mohamed MEH (1996). Clinical and epizootiological features of camelpox in eastern Sudan. J. Camel Prac. Res. (2); 99-102.

• Khanna ND, Uppal PK, Sharma N, Tripathi BN (1996). Occurrence of pox infections in camels. Ind. Vet. J. 73(8): 813–817.

• Klopries M (1993). Etablierung und Charakterisierung einer Kamelhautzelllinie (Dubca). Vet. Med. Dissertation, Munchen.

• Kolhapure RM, Deolankar RP, Tupe CD, Raut CG, Basu A, Dama BM, Pawar SD, Joshi MV, Padbidri VS, Goverdhan MK, Banerjee K (1997). Investigation of buffalopox outbreaks in Maharashtra state during 1992–1996. Indian J. Med. Res. 106: 441–446.

• Križ B (1982). A study of camelpox in Somalia. J. Comp. Pathol. 92: 1–8. http://dx.doi.org/10.1016/0021-9975(82)90037-8

• Kroon EG, Mota BE, Abrahao JS, da Fonseca FG, de Souza Trindade G (2011). Zoonotic Brazilian vaccinia virus: from field to therapy. Antiviral Res. 92: 150–63. http://dx.doi.org/10.1016/j.antiviral.2011.08.018

• Kumar A, Yadav MP, Chandra R, Garg SK (1987). Clinicoepidemiological features of a pox outbreak among buffaloes. Ind. J. Anim. Health. 26: 41–45.

• Lal SM, Singh IP (1973). Serological characterization of buffalopox virus. Archiv fur die gesamte Virusforschung. 43: 396. http://dx.doi.org/10.1007/BF01556157

• Lal SM, Singh IP (1977). Buffalo pox – a review. Trop. Anim. Health. Prod. 9: 107–112. http://dx.doi.org/10.1103/PhysRevA.15.2566

• Lapas I, Mikheev M, Shchelkunov S, Mikhailovich V, Sobolev A, Blinov V, Babkin L, Guskov A, Sokunova E, Zasateliev A, Sandakhchiev L, Mirzabekov A (2002). Species-level identification of orthopoxviruses with an oligonucleotide. Microchip J. Clin. Microbiol. 40: 753-757. http://dx.doi.org/10.1038/embi.2012.47

__October 2015 | Volume 3 | Issue 10 | Page 539__
• Leese S (1909). Two diseases of young camels. J. Trop. Vet. Sci. 4: 1.
• Mallick KP (1988). A note on epidemiological study of an outbreak of buffalopox. Indian J. Vet. Med. 8: 146–147.
• Mallick KP, Dwivedi SK (1982). Clinical observations in an outbreak of buffalopox. Indian Vet. J. 59: 397–398.
• Marrennikova SS (1975). The results of examinations of wildlife monkeys for the presence of antibodies and viruses of the pox group. Vopr. Virusol. 3: 321-326.
• Marodam V, Nagendra Kumar SB, Tanwar VK, Thigagaraj D, Reddy GS, Tanwar RK, Srinivasan VA (2006). Identification and characterization of camelpox virus. Indian J. Anim. Sci. 76: 326–327.
• Marrenikova SS, Shenkman LS, Shelukhina EM, Malsova NN (1974). Isolation of camelpox virus and investigation of its properties. Acta Virol. 18: 423–428.
• Mathew T (1975). Immunological studies on pox group of viruses with special reference to buffalo pox virus. Indian Vet. J. 52: 517–525.
• Meena ML (2014). Adoption level of camel farming practices in arid zone of Rajasthan, India. Int. J. Extens. Educ. 10: 176–180.
• Mehrrota ML, Verma KC, Somvanshi R (1981). Isolation and characterization of buffalopox virus from an outbreak among buffaloes in Northern India. Ind. Vet. Med. J. 5: 155–159.
• Meyer H, Pfeffer M, Reitha HJ (1994). Sequence alterations within and downstream of the A-type inclusion protein genes allow differentiation of Orthopoxvirus species by polymerase chain reaction. J. Gen. Virol. 75: 1975–1981. http://dx.doi.org/10.1099/0022-1317-75-8-1975.
• Milton AAP, Priya GB, Aravind M, Parthasarathy S, Saminathan M, Jeeva K, Agarwal RK (2015). Nosocomial infections and their surveillance in veterinary hospitals. Adv. Anim. Vet. Sci. 3(2): 1–24. http://dx.doi.org/10.14737/journal.aavs/2015/3.2.1.24
• Mohanty PK, Rai A, Goel AC (1989a). Assay of immune response of buffalo pox virus in rabbits and buffaloes using b-propiolactone and formalin inactivated Vero cell culture vaccine. Indian J. Virol. 5(1–2): 21–29.
• Mohanty PK, Rai A (1989b). Immune response induced by Vero cell culture adapted buffalo pox virus in rabbits and buffaloes. Indian J. Exp. Biol. 27(4): 350–355.
• Muraleedharan K, Raghavan R, Murthy GVK, Murthy VSS, Balamurugan V (1998). Diagnostic procedures for poxvirus infections in camelds. J. Camel Pract. Res. 5(2): 189–195.
• Prabhu M, Bhanuprakash V, Venkatesan G, Yogisharadhya R, Balamurugan V (2014). Evaluation of stability of live attenuated camelpox vaccine stabilized with different stabilizers and reconstituted with various diluents. Biologicals. 42: 169–175. http://dx.doi.org/10.1016/j.biologicals.2014.02.001.
• Prabhu M, Siva Sankar MS, Bhanuprakash V, Venkatesan G, Bora DP, Balamurugan V (2012). Real time PCR: A rapid tool for potency estimation of live attenuated camelpox and buffalopox vaccines. Biologicals. 40: 92–95. http://dx.doi.org/10.1016/j.biologicals.2011.09.012.
• Ramakrishna M, Ananthapadmanabham K (1957). An experimental study of virus of buffalopox. Ind. Vet. J. 34: 23–30.
• Ramyar H, Hessami M (1972). Isolation, cultivation and characterisation of camelpox virus. Zentralblatt für Veterinarmedizin. 19: 182. (Cited in Veterinary Bull.). 42: 2741.
• Raut CG, Tatwarti SB, Deslankar RP, Kolhapure RM, Tupe CD (1997). Buffalo pox zoonosis in Nasik suburb (Maharashtra State). Livest. Int. 1: 19.
• Renner- Muller IC, Meyer H, Munz E (1995). Characterization of camelpoxvirus isolates from Africa and Asia. Vet. Microbiol. 45: 371–381.
• Rheinbaden FV, Gebel J, Exner, Schmidt A (2007). Environmental resistance, disinfection, and sterilization of poxviruses. In: Schmidt AA, Weber A, Mercer O, editors. Poxviruses. Basel: Birkhauser Verlag: p. 397–405.
• Ramakrishna M, Ananthapadmanabham K (1957). An experimental study of virus of buffalopox. Ind. Vet. J. 34: 23–30.
• Roppe F, Altenburger P, Juma, Njuki A (1995). Polymerase chain reaction strategy for identification and differentiation of smallpox and other orthopoxviruses. J. Clin. Microbiol. 33: 2069–2076.
• Sadovsky RG (1970). Cultivation of camelpox virus in chick embryos. In: Virovye Bolenez Selskikh zhivotnykh, Part I, p. 55, (in Russian) Moscow.
• Schgal CL (1977). Camelpox. In Report of Summer Institute on Animal Poxviruses, 161-163, G.B. Pant University of Agriculture and Technology, India.
• Schgal CL, Ray SN, Ghosh TK, Arora RR (1977). In: Ramakrishna M, Ananthapadmanabham K (1957). An experimental study of virus of buffalopox. Ind. Vet. J. 34: 23–30.
• Sharma GK (1934). An interesting outbreak of variola vaccinia in milch cattle of Lahore. The Imperial Council of Agricultural Veterinary Sciences, 11: 467–471.
• Shchelkunov SN (2013). An increasing danger of zoonotic orthopoxvirus infections. PLOS pathogens. 9(2): 1-4. e1003756.

• Sheikh A, HM, Khalafla AI, Nimir AH (2009). Detection of camel pox and vaccinia viruses by polymerase chain reaction. Trop. Anim. Health. Prod. 41(8): 1637–1641. http://dx.doi.org/10.1007/s11250-009-9359-y

• Singh IP, Singh SB (1967). Isolation and characterization of the aetiologic agent of buffalopox. J. Res. Ludhiana. 4: 440.

• Singh RK, Balamurugan V, Bhanuprakash V, Venkatesan G, Hosamani M (2012). Emergence and re-emergence of vaccinia-like viruses: global scenario and perspectives. Indian J. Virol. 23(1): 1-11. http://dx.doi.org/10.1007/s13337-012-0068-1

• Singh RK, Hosamani M, Balamurugan V, Satheesh CC, Shingal KR, Tatwari SB, Bambal RG, Ramteke V, Yadav MP (2006a). An outbreak of Buffalopox in buffalo (Bubalus bubalis) dairy herds in Aurangabad, India. Sci. Tech. Rev. O.I.E. 25: 981–987.

• Singh RK, Hosamani M, Balamurugan V, Satheesh CC, Rasool TJ, Yadav MP (2006b). Comparative sequence analysis of envelope protein genes of Indian Buffalopox virus isolates. Arch. Virol. 151: 1995–2005. http://dx.doi.org/10.1007/s00705-006-0761-8

• Singh RK, Balamurugan V, Hosamani M, Satheesh CC, Rasool TJ, Yadav MP (2006c). Comparative polypeptide profiling: isolation, propagation and purification of Indian isolates of buffal pox virus. J. Anim. Vet. Adv. 5: 260–265.

• Singh RK, Hosamani M, Balamurugan V, Bhanuprakash V, Rasool TJ, Yadav MP (2007a). Buffalopox: An emerging and re-emerging zoonosis. Anim. Health Res. Rev. 8(1): 105–114. http://dx.doi.org/10.1017/S1466252307001259

• Singh RK, Balamurugan V, Hosamani M, De UK, Chandra Naik BM, Krishnappa G, Yadav MP (2007b). BSR gene based sequence analysis of Indian buffalopox virus isolates in relation to other orthopoxviruses. Acta Virol. 51: 47–50.

• Singh RK, Balamurugan V, Hosamani M, Kallesh DJ, Bhanuprakash V (2008). Sequence analysis of C18L gene of buffalopox virus: PCR strategy for specific detection and differentiation of buffalopox from orthopoxviruses. J. Virol. Method. 154(1-2): 146–153. http://dx.doi.org/10.1016/j.jviromet.2008.08.009

• Smeef DFR, Sidwell W, Kefaever D, Bray M, Huggins JW (2002). Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46: 1329–1335. http://dx.doi.org/10.1128/AAC.46.5.1329-1335.2002

• Tadjbahsh H (1994). Traditional methods used for controlling animal diseases in Iran. Revue de Science et Technologie 13: 599–614.

• Tantawi HH, El-Dahaby H, Fahmy LS (1978). Comparative studies on poxvirus strains isolated from camels. Acta Virol. 22: 451–457.

• Tantawi HH, Saban MS, Reda IM, El-Dahaby H (1974). Camelpox virus in Egypt I – Isolation and Characterization. Bull. Epizoot. Dis. Africa. 22(4): 315–319.

• Van Regenmortel MHV, Fauquet CM, Bishop DHL (2000). Virus taxonomy: Seventh Report of the International committee on taxonomy of Viruses. Academic Press, San Diego.

• Venkatesan G, Balamurugan V, Gandhale PN, Singh RK, Bhanuprakash V (2010a). Viral zoonosis: a comprehensive review. J. Vet. Anim. Adv. 5(2): 77–92. http://dx.doi.org/10.3923/ajava.2010.77.92

• Venkatesan G, Balamurugan V, Prabhu M, Yogisharadhyra R, Bora DP, Gandhale PN, Sankar MS, Kularkarin AM, Singh RK, Bhanuprakash V (2010b). Emerging and re-emerging zoonotic buffalopox infection: a severe outbreak in Kolhapur (Maharashtra), India. Vet. Ital. 46(4): 439–448.

• Venkatesan G, Balamurugan V, Balamurugan V, Prabhu M, Pandey AB (2012a). TaqMan hydrolysis probe based real time PCR for detection and quantitation of camelpox virus in skin scabs. J. Virol. Method. 181(2): 192–196. http://dx.doi.org/10.1016/j.jviromet.2012.02.002

• Venkatesan G, Balamurugan V, Balamurugan V, Singh RK, Pandey AB (2012b). Development of loop-mediated isothermal amplification assay for specific and rapid detection of camelpox virus in clinical samples. J. Virol. Method. 183(1): 34–39. http://dx.doi.org/10.1016/j.jviromet.2012.03.019

• Wariyar KC (1937). Variola in buffaloes. Ind. Vet. J. 14: 169–170.

• Wernery U, Kaaden OR, Ali M (1997a). Orthopox virus infections in dromedary camels in United Arab Emirates (U.A.E.) during winter season. J. Camel Pract. Res. 4(1): 51–55.

• Wernery U, Kaaden OR (2002). Camel pox. In: Infectious Diseases in Camelids, Second Edition, Wernery U. and Kaaden OR, eds. Blackwell Science Berlin, Vienna, 176–185.

• Wernery U, Kaaden OR (1995). Infectious diseases of camels. Blackwell Scientific, Oxford, UK.

• Wernery U, Kinne J, Zachariah R (2000). Experimental camelpox infection in vaccinated and unvaccinated guanacos. J. Camel Pract. Res. 7(2): 149–152.

• Wernery U, Meyer H, Pfeffer M (1997b). Camel pox infection in vaccinated and unvaccinated dromedaries. J. Vet. Med. [B] Infect. Dis. 46(2): 131–136.

• Woolhouse ME, Gowtage-Sequeria S (2005). Host range and re-emerging pathogens. Emerg. Infect. Dis. 11: 1842–1847. http://dx.doi.org/10.3201/eid1112.050997

• Yadav S, Hosamani M, Balamurugan V, Bhanuprakash V, Singh RK (2010). Partial genetic characterization of viruses isolated from poxlike infection in cattle and buffaloes: evidence of buffalo pox virus circulation in Indian cows. Arch. Virol. 155(2): 255–261. http://dx.doi.org/10.1007/s00705-009-0562-y

• Zafar A, Swanepoel R, Hewson R, Nizam M, Ahmed A, Hussain A, Grobbelaar A, Bewley K, Mioulet V, Dowsett B, Easterbrook L, Hasan R (2007). Nosocomial buffalopoxvirus infection, Karachi, Pakistan. Emerg. Infect. Dis. 13(6): 902–904. http://dx.doi.org/10.3201/eid1306.061068